ATI 355

Drug Profile

ATI 355

Alternative Names: Anti NOGO-A mAb; Anti-Nogo antibody; ATI355

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action Nerve growth factor stimulants; Nogo protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Spinal cord injuries

Most Recent Events

  • 30 Sep 2011 Novartis completes a phase I trial in Spinal cord injuries in USA, Canada, Switzerland, Germany & Spain (NCT00406016)
  • 20 Oct 2008 ATI 355 received Orphan Drug status for Spinal cord injuries in USA
  • 20 Jun 2008 Enrolment is ongoing for a phase I trial in Spinal cord injuries at sites in Germany, Switzerland and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top